secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001104659-26-023484
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec announces TGH Cancer Institute study of PEDMARK for ototoxicity in AYA and adult patients
--------------------------------------------------------------------------------

- Tampa General Hospital Cancer Institute initiates real-world study of PEDMARK (sodium thiosulfate) to reduce ototoxicity risk in AYA and adult patients receiving cisplatin.
- Study aims to evaluate clinical utility and audiology monitoring to inform future research on hearing loss prevention.
- PEDMARK currently FDA-approved for pediatric patients 1 month+ with localized non-metastatic solid tumors; NCCN 2A recommendation for AYA.
- Gene A. Wetzstein, PharmD, BCOP, of TGH Cancer Institute is principal investigator; Fennec's CMO Pierre Sayad comments on real-world evidence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926023484/0001104659-26-023484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926023484/fencf-20260304x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-023484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer